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WORKSHOP ON THE ENHANCEMENT OF CHEMOTHERAPY
BY NITROIMIDAZOLES
Held at the Gray Laboratory, Northwood on 25 June 1981
(Attended by about 20 contributors and 30 discussants)
ROSE et al. (1980) observed a remark-
able enhancement ofmelphalan damage in
mouse tumours, by a DMF of about 2,
when 1 mg/g of misonidazole (MISO) was
given 30 min before the melphalan. They
did not find normal tissue damage to be
enhanced by more than 1 4-1 5, giving a
clear therapeutic gain. Tannock (1980)
however, obtained DMF's which were
similar for tumour response, weight loss
and leukopenia in his mice, suggesting no
therapeutic gain with cyclophosphamide
(CY) and BCNU. This workshop was held
to review the present state of the field.
Most of the active British workers par-
ticipated together with Dr J. Martin
Brown from Stanford and Dr Dietmar
Siemann from Rochester.
Three workers presented in vitro data
and over a dozen presented in vivo results
using mice. The reports covered 10 types
of tumour in 6 strains of mice and 2
human tumour xenografts in immune-
suppressed mice (Clutterbuck & Millar).
The sensitization of 10 anti-cancer drugs
by 6 different radiosensitizers had been
investigated (not in every combination).
Little of the work reported had been
published.
It was clear that misonidazole (MISO)
enhances the effect of bifunctional alky-
lating agents, e.g. cyclophosphamide, mel-
phalan, chlorambucil, CCNU and (less so)
BCNU, but not cis-platinum, Adriamycin
or bleomycin in vivo. In addition, 5-
fluorouracil and vincristine have shown
enhancement, even though they were not
bifunctional alkylating agents.
The enhancement was greater in experi-
mental tumours than in normal tissues in
mice in nearly all the experiments (see
below), so there seemed to be a real
prospect of therapeutic gain. Enhance-
ments in vitro as high as 5-fold (ratio
of drug dose without to dose with MISO,
to produce a given proportion of cell
kill were reported). In vivo, enhance-
ments in tumours varied from 1 2 to 3-1,
depending greatly on the type of tumour.
Few differences were found between
regrowth delay in situ and cell survival
after excising the treated tumours as the
assay, but ifanything regrowth delaygave
lower enhancement ratios.
In most experiments, little or no
enhancement of normal tissue injury was
seen: CFUs: Stephens, Hendry, Spooner,
Clutterbuck & Millar, and Brown at low
doses of CCNU (but appreciable enhance-
ment at high doses); Peripheral white cells:
Martin, McNally, Twentyman, Peacock,
Clutterbuck & Millar; Siemann obtained a
factor of 1 2-1 4 and Hirst (Stanford)
found no change in total leucocytes but
significant depression ofneutrophils alone;
Intestinal clones: Hendry, Siemann 1 2-
1-4; Testis: Hendry, Hirst & Brown;
LD50: Sheldon, 1 25; Randhawa & Dene-
kamp, 1-7 and 1-9 (but tumour DMFs were
2-3 and 3'1, so that therapeutic gain
factors were 1-2 and 1.8) another tumour
showed gain factors of only 0-9-1.4, the
worst reported.
In most experiments, but not all, the
tumour enhancement increased with dose
of MISO only above a threshold dose of
0 3-0 5 mg/g. Then, if the dose-response
curves rose in parallel, the "enhancement
ratio" would decrease for higher doses of
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postulated that the short half-life of
sensitizers in mice might be the cause of
this apparent threshold.
Other radiosensitizers had similar effects
to MISO, but few had been found to be
consistently better in vivo. The enhance-
ment did not increase with electron affinity
(as radiosensitizing ability does) but the
toxicity did. In some experiments (Shel-
don) the sensitizers Ro 03-8799, Ro 03-
8800, RSU 1047, and Ro 07-1051 gave
higher enhancement of melphalan than
given by MISO. In other types of tumour
(Randhawa and Denekamp) such com-
pounds were as good as MISO but no
better; in others MISO was best (Siemann).
The optimum interval for most combina-
tions appeared to bewhenthesensitizerwas
given -1-2 h before the chemotherapeutic
drug (e.g. Law, using SR 2508 and CY).
The drop in body temperature that was
caused by some sensitizers was not related
to the enhancement (Siemann, Law,
Stephens).
The enhancement was small in very
small tumours (, 1 mm diameter); this
confirmed the in vitro finding that hypoxia
was necessary. However, higher propor-
tions of cells were killed than the hypoxic
proportion, so presumably some substance
diffused out of hypoxic regions.
An important point about the in vivo
work was that the half-life of nitroimida-
zoles in mice is up to 10 times shorter than
in man. Any effect requiring lengthy pre-
incubation will therefore be underesti-
mated in mice (in contrast to radio-
sensitization which takes only milli-
seconds after the sensitizer has diffused to
the hypoxic cell). The fact that enhance-
ments reported in vitro were obtained
even in cells from which the sensitizer had
been washed out before a chemothera-
peutic drug was added (provided the
sensitizer had been present for some hours
beforehand) showed that pre-incubation
was more important than presence at the
time of giving the other drug.
Possible mechanisms discussed (especi-
ally by Brown, Adams and Siemann)
included:
(a) Selective killing of hypoxic cells.
(b) Sensitization ofdrug-resistant hypoxic
cells.
(c) Pharmacokinetic changes in the
chemotherapeutic drug due to the
nitroimidazole.
(d) Pre-incubation toxicity, as observed
in vivo.
(e) Prevention ofrepair ofthe potentially
lethal damage caused by the chemo-
therapeutic drug.
There was agreement that (a) and (b)
were not dominant. There was disagree-
ment about the predominance of (d) or (e),
but some tumours with no PLD repair
did show enhancement (e.g. the LL
tumour used by Stephens and Spooner)
so that (e) could not be the only important
process. There was also disagreement
about (c): Workman reported high en-
hancement in tumours using the non-
radiosensitizing inhibitor of liver meta-
bolism, SKF 525A, but the rationale for
any therapeutic gain was at present
unknown.
Brown (Stanford) and Pederson (Ed-
monton) had found no pre-incubation
effect in vivo for radiosensitizers, using
radiation. Hence the existence of a pre-
incubation effect in vitro does not mean
that it will occur in vivo. This may be
because of a different type ofhypoxic cell,
if hypoxia is cyclic, or because of the
short half-life in mice.
In discussing which chemotherapeutic
agents are enhanced and why, it was
clear that alkylating agents were en-
hanced; perhaps because a toxic product
ofnitroimidazoles, metabolized in hypoxic
conditions, attacks DNA and makes it
more sensitive to cross-linking agents.
More studies are necessary to distinguish
between alkylation and carbamylation
(Siemann).
Some Phase I clinical work was des-
cribed by McElwain (MISO +melphalan)
and by Spooner & Peckham (MISO +
5FU).
It was concluded that enhancements
were generally greater in tumours than in
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normal tissues, so that therapeutic advan-
tages may be possible, but that more work
on normal tissues was necessary, as well as
on mechanisms ofthe enhancement.
It was agreed that the discussions were
stimulating and the Cancer Research
Campaign was thanked for supporting the
meeting.
Reported by J. F. FOWLER
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